Stockholm, Sweden, January 20, 2026. Affibody Medical AB (publ) (“Affibody”) today announced that the Board of Directors, with authorization from the annual general meeting on May 27, 2025, has resolved to carry out a fully guaranteed rights issue of SEK 307 million.

Affibody’s main shareholder Patricia Industries, part of Investor AB, has via its subsidiary Duba AB committed to subscribe for its pro rata share, as well as any remaining shares not subscribed for by other shareholders. The full amount of the rights issue is thus guaranteed. Payment for the new shares is expected to comprise of approximately 120 MSEK in cash and 190 MSEK in conversion of shareholder loans.

The purpose of the rights issue is to finance the evaluation of higher radioactivity levels in the ongoing Phase 1 clinical study with the HER2 targeting Radioligand Therapy (RLT) candidate ABY-271 in metastatic breast cancer, as well as to support broadening of Affibody’s RLT pipeline.

“In December we reported highly encouraging initial results from the first cohort of patients in our ongoing Phase 1 study of ABY-271 in HER2-positive metastatic breast cancer. The clinical data is very well aligned with preclinical findings, validating the Affibody® platform as a foundation for next-generation RLTs,” said David Bejker, CEO of Affibody. “The new financing will allow us to accelerate the Phase 1 study by evaluating higher radioactivity levels as well as expanding our RLT portfolio.”

Record day for the rights issue will be January 23, 2026, and shareholders registered on the record day will receive information on how to participate in the rights issue via their custodian.

About Affibody

Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody® molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody’s lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2 positive metastatic breast cancer.

The Affibody® platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.

Affibody’s main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

Disclaimer

This press release contains forward-looking statements. While Affibody considers the projections to be based on reasonable assumptions, forward-looking statements are subject to both known and unknown risks and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

This press release does not constitute or form part of any offer or invitation to purchase or subscribe for any securities. No assurance shall be given in connection with the information in this press release regarding its accuracy or completeness. Investors shall conduct all investment decisions independently.

Contacts (Affibody)

David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044

Contacts (Media)

Richard Hayhurst, 59° North Communications, richard.hayhurst@59north.bio, +44 (0) 7711 8215727

Attachments

Affibody Carries Out Fully Guaranteed Rights Issue of SEK 307 Million

Läs mer på MFN